- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02411695
Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC- 34712) in Adolescents With Schizophrenia
February 14, 2017 updated by: Otsuka Pharmaceutical Development & Commercialization, Inc.
A Phase 1, Multicenter, Open-label, Dose-Escalation Trial to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC- 34712) in Adolescents With Schizophrenia
The purpose of this study is to assess the safety, tolerability and pharmacokinetics (PK) of oral brexpipirazole in adolescent subjects with schizophrenia or Other Related Psychiatric Disorders.
Study Overview
Detailed Description
Schizophrenia is a severely delibitating mental illness that affects approximately 1% of the world population.
The onset of schizophrenia symptoms typically peaks in late adolescence and early adulthood.
In a minority of cases, the initial episode may occur during childhood or early adolescence.
Patients who experience this "early-onset schizophrenia" exhibit symptoms that are more severe and follow a more chronic course; adolescents with schizophrenia may never achieve full remission of the initial episode.
The prognosis for early-onset schizophrenia tends to be poor, and cognitive impairment is greater compared with individuals whose onset of schizophrenia occurs later in life.
Several antipsychotics have been investigated for the treatment of adolescent schizophrenia, however, there is a particular challenge because developing bodies are more sensitive to side effects of antipsychotics, particularly with respect to weight gain.
In order to enroll a population that includes the younger ages, adolescents with other related psychiatric disorders are also included in this study.
Study Type
Interventional
Enrollment (Anticipated)
40
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72211
-
-
California
-
Culver City, California, United States, 90230
-
Orange, California, United States, 92858
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20016
-
-
Georgia
-
Atlanta, Georgia, United States, 30331
-
-
New Jersey
-
Marlton, New Jersey, United States, 08053
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
-
Cleveland, Ohio, United States, 44106
-
-
Texas
-
The Woodlands, Texas, United States, 77381
-
-
Utah
-
Orem, Utah, United States, 84058
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
11 years to 15 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male and female subjects 13 to 17 years of age, inclusive, at the time of informed consent.
- Subjects with a current diagnosis of primary schizophrenia spectrum or bipolar spectrum disorder, as defined by DSM-IV-TR criteria, and confirmed by K-SADS-PL.
- No psychiatric hospitalizations within the past 12 weeks.
- Subjects require treatment with antipsychotic medications.
- Subjects who have received previous outpatient antipsychotic treatment at an adequate dose for an adequate duration (at least 6 weeks) and who showed a previous good response to such antipsychotic treatment (other than clozapine) in the last 12 months.
- Subjects with a body weight at Screening greater than or equal to 30 kg.
Exclusion Criteria:
- Sexually active females of childbearing potential and male subjects who are not practicing two different methods of birth control with their partner (or abstinence) during the trial and for 30 days after the last dose of trial medication
- Females who are breast-feeding and/or who have a positive pregnancy test result prior to receiving trial drug.
- Subjects who have received continuous medication therapy to treat schizophrenia and schizophrenia spectrum diagnosis for less than six months prior to first dose of study medication AND subjects who have received continuous medication therapy to treat bipolar and bipolar spectrum disorder for less than two months in the past three years; or subjects who require more than one antipsychotic..
- Subjects with a current DSM-IV-TR diagnosis other than schizophrenia spectrum , bipolar spectrum, including any Axis I or Axis II (DSM-IV-TR) disorder.
- Subjects with a clinical presentation and/or history of any neurodevelopmental disorder
- Subjects who have met DSM-IV-TR criteria for substance abuse or dependence within the past 180 days.
- Subjects who currently have clinically significant neurological, hepatic, renal, metabolic, hematological, immunological, cardiovascular, pulmonary, or gastrointestinal disorders such as any history of myocardial infarction, congestive heart failure, HIV seropositive status/acquired immunodeficiency syndrome, or chronic hepatitis B or C.
- Subjects with IDDM (ie, any subjects using insulin) are excluded. Subjects with non-IDDM may be eligible for the trial if their condition is stable.
- Subjects with epilepsy or a history of seizures.
- Any major surgery or blood transfusion within 30 days prior to first dose of trial medication.
- Subjects with a positive drug screen for cocaine or other illicit drugs, or alcohol are excluded and may not be retested or re-screened.
- Prohibited concomitant medications used within the exclusionary period prior to Day 1 of the Dose Escalation Phase or anticipated need for such medications during the trial.
- Subjects who participated in a clinical trial and were exposed to IMP within the last 30 days or who participated in more than two interventional clinical trials within the past year.
- Subjects with a history of true allergic response (ie, not intolerance) to more than one class of medications.
- Inability to tolerate oral medication or swallow tablets.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1
0.5 mg, Brexpipraxzole (OPC-34712)
|
Subjects who are deemed eligible for the trial will be assigned to a dosing cohort and will enter a Dose Titration Phase during which they will receive a starting dose of brexpiprazole for 2 to 10 days based on their assigned titration schedule.
The Dose Titration Phase may be extended up to a maximum of 14 days, based on the observed safety and tolerability profile of the previous cohort's Dose Titration Phase.
Following the Dose Titration Phase, subjects will enter the Fixed Dose Phase and will be administered the assigned dose for that cohort for 14 days.
|
Experimental: Cohort 2
1mg, Brexpipraxzole (OPC-34712)
|
Subjects who are deemed eligible for the trial will be assigned to a dosing cohort and will enter a Dose Titration Phase during which they will receive a starting dose of brexpiprazole for 2 to 10 days based on their assigned titration schedule.
The Dose Titration Phase may be extended up to a maximum of 14 days, based on the observed safety and tolerability profile of the previous cohort's Dose Titration Phase.
Following the Dose Titration Phase, subjects will enter the Fixed Dose Phase and will be administered the assigned dose for that cohort for 14 days.
|
Experimental: Cohort 3
2mg, Brexpipraxzole (OPC-34712)
|
Subjects who are deemed eligible for the trial will be assigned to a dosing cohort and will enter a Dose Titration Phase during which they will receive a starting dose of brexpiprazole for 2 to 10 days based on their assigned titration schedule.
The Dose Titration Phase may be extended up to a maximum of 14 days, based on the observed safety and tolerability profile of the previous cohort's Dose Titration Phase.
Following the Dose Titration Phase, subjects will enter the Fixed Dose Phase and will be administered the assigned dose for that cohort for 14 days.
|
Experimental: Cohort 4
3 mg, Brexpipraxzole (OPC-34712)
|
Subjects who are deemed eligible for the trial will be assigned to a dosing cohort and will enter a Dose Titration Phase during which they will receive a starting dose of brexpiprazole for 2 to 10 days based on their assigned titration schedule.
The Dose Titration Phase may be extended up to a maximum of 14 days, based on the observed safety and tolerability profile of the previous cohort's Dose Titration Phase.
Following the Dose Titration Phase, subjects will enter the Fixed Dose Phase and will be administered the assigned dose for that cohort for 14 days.
|
Experimental: Cohort 5
4mg, Brexpipraxzole (OPC-34712)
|
Subjects who are deemed eligible for the trial will be assigned to a dosing cohort and will enter a Dose Titration Phase during which they will receive a starting dose of brexpiprazole for 2 to 10 days based on their assigned titration schedule.
The Dose Titration Phase may be extended up to a maximum of 14 days, based on the observed safety and tolerability profile of the previous cohort's Dose Titration Phase.
Following the Dose Titration Phase, subjects will enter the Fixed Dose Phase and will be administered the assigned dose for that cohort for 14 days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reported Adverse Events (AEs) at 30 day Follow-Up
Time Frame: 30 day Follow-Up
|
30 day Follow-Up
|
|
Change from Baseline to Day 17 in Vital Signs
Time Frame: Baseline to Day 17
|
Baseline to Day 17
|
|
Change from Baseline to Day 17 ECGs
Time Frame: Baseline to Day 17
|
Baseline to Day 17
|
|
Change from Baseline to Day 17 Hematology
Time Frame: Baseline to Day 17
|
Baseline to Day 17
|
|
Change from Baseline to Day 14 Physical examination
Time Frame: Baseline to Day 14
|
Baseline to Day 14
|
|
Change from Baseline to Day 17 Body weight
Time Frame: Baseline to Day 17
|
Baseline to Day 17
|
|
Change from Baseline to Day 17 Serum chemistry
Time Frame: Baseline to Day 17
|
Including Prolactin concentrations
|
Baseline to Day 17
|
Change from Baseline to Day 17 Urinalysis
Time Frame: Baseline to Day 17
|
Baseline to Day 17
|
|
Maximal peak steady-state plasma concentration
Time Frame: At Day 14
|
At Day 14
|
|
Minimum trough steady-state plasma concentration
Time Frame: At Day 14
|
At Day 14
|
|
Time to maximum peak steady-state plasma concentration
Time Frame: At Day 14
|
At Day 14
|
|
Area under the concentration-time curve during the dosing interval at steady-state
Time Frame: At Day 14
|
At Day 14
|
|
Terminal elimination half-life
Time Frame: At Day 14
|
At Day 14
|
|
For Brex only, apparent cleanse and apparent volume of distribution
Time Frame: At Day 14
|
At Day 14
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Mean change in CGI-S score
Time Frame: Day -1 of Dose Titration Phase to Day 7 and Day 14 of Fixed Dose Phase
|
Day -1 of Dose Titration Phase to Day 7 and Day 14 of Fixed Dose Phase
|
Mean change in CGI-I score
Time Frame: Day 7 and Day 14
|
Day 7 and Day 14
|
Glycosylated haemoglobin [HbA1c]
Time Frame: Baseline to Day 17
|
Baseline to Day 17
|
Change from Baseline to Day 17 Adrenocorticotropic hormone [ACTH]
Time Frame: Baseline to Day 17
|
Baseline to Day 17
|
Change from Baseline to Day 17 Cortisol
Time Frame: Baseline to Day 17
|
Baseline to Day 17
|
Change from Baseline to Day 17 Thyroid stimulating hormone [TSH]
Time Frame: Baseline to Day 17
|
Baseline to Day 17
|
Change from Baseline to Day 17 Prothrombin time [PT]
Time Frame: Baseline to Day 17
|
Baseline to Day 17
|
Change from Baseline to Day 17 Activated partial thromboplastin time [aPTT]
Time Frame: Baseline to Day 17
|
Baseline to Day 17
|
Change from Baseline to Day 17 International normalized ratio [INR]
Time Frame: Baseline to Day 17
|
Baseline to Day 17
|
For subjects with a current primary schizophrenia spectrum diagnosis, mean change in Positive and Negative Syndrom Scale (PANSS)
Time Frame: Day-1 to Day 15
|
Day-1 to Day 15
|
For subjects with a current diagnosis of bipolar spectrum disorder, mean change in Young Mania Rating Scale (YMRS)
Time Frame: Day -1 to Day 15
|
Day -1 to Day 15
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Study Director: Eva Kohegyi, MD, Otsuka Pharmaceutical Development & Commercialization
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2015
Primary Completion (Actual)
January 1, 2017
Study Completion (Actual)
January 1, 2017
Study Registration Dates
First Submitted
May 30, 2014
First Submitted That Met QC Criteria
April 2, 2015
First Posted (Estimate)
April 8, 2015
Study Record Updates
Last Update Posted (Actual)
February 15, 2017
Last Update Submitted That Met QC Criteria
February 14, 2017
Last Verified
February 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 331-10-233
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Bradley LegaRecruiting
-
All India Institute of Medical Sciences, BhubaneswarRecruitingTreatment Resistant SchizophreniaIndia
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruitingTreatment-resistant Schizophrenia | Healthy Controls | Treatment-responsive SchizophreniaUnited Kingdom
-
University of Sao PauloUnknownRefractory Schizophrenia | Super Refractory SchizophreniaBrazil
-
Rakitzi, StavroulaActive, not recruiting
-
Peking UniversityNot yet recruitingTreatment-resistant Schizophrenia
-
Ohio State UniversityRecruitingTreatment-resistant SchizophreniaUnited States
-
University Hospital, BrestRecruitingSchizophrenia | Schizophrenia Prodromal | Schizophrenia, ChildhoodFrance
Clinical Trials on Brexpiprazole (OPC-34712)
-
Otsuka Pharmaceutical Development & Commercialization...CompletedAcute SchizophreniaKorea, Republic of, United States, Serbia, Ukraine, Romania, Poland, Canada, Latvia, Japan
-
Otsuka Pharmaceutical Co., Ltd.CompletedHealthy Adult MaleJapan
-
Otsuka Pharmaceutical Co., Ltd.Completed
-
Otsuka Pharmaceutical Development & Commercialization...CompletedSchizophreniaUnited States, Bulgaria, Philippines, Romania, Russian Federation, Serbia, Croatia, India, Korea, Republic of, Slovakia, Taiwan, Ukraine
-
Otsuka Pharmaceutical Development & Commercialization...CompletedSchizophreniaKorea, Republic of, United States, Philippines, Malaysia, Croatia, Serbia, Russian Federation, Ukraine, Romania, Puerto Rico, Colombia, Turkey, Poland, Taiwan, Canada, Latvia, Slovakia, Mexico, Japan
-
Otsuka Pharmaceutical Development & Commercialization...CompletedSchizophrenia | Psychiatric DisordersUnited States
-
Otsuka Pharmaceutical Development & Commercialization...CompletedSchizophreniaUnited States
-
Otsuka Pharmaceutical Development & Commercialization...Otsuka Pharmaceutical Co., Ltd.Completed
-
Otsuka Pharmaceutical Development & Commercialization...CompletedAcute SchizophreniaUnited States, Philippines, Taiwan, Russian Federation, Croatia, Colombia, Mexico, Slovakia
-
Otsuka Pharmaceutical Co., Ltd.Completed